IL204948A - Β - single ifn from one to a mutated fc lgg segment - Google Patents

Β - single ifn from one to a mutated fc lgg segment

Info

Publication number
IL204948A
IL204948A IL204948A IL20494810A IL204948A IL 204948 A IL204948 A IL 204948A IL 204948 A IL204948 A IL 204948A IL 20494810 A IL20494810 A IL 20494810A IL 204948 A IL204948 A IL 204948A
Authority
IL
Israel
Prior art keywords
lgg
mutated
fragment
fused
single ifn
Prior art date
Application number
IL204948A
Other languages
English (en)
Hebrew (he)
Other versions
IL204948A0 (en
Inventor
Peter Hjelmstrom
Markus Imhof
George Feger
Nigel Jenkins
Phillippe Dupraz
Christine Power
Laurent Magenant
Phillippe Chatellard
Renata Pankiewicz
Vincent Dechavanne
Original Assignee
Merck Serono Sa
Peter Hjelmstrom
Markus Imhof
George Feger
Nigel Jenkins
Phillippe Dupraz
Christine Power
Laurent Magenant
Phillippe Chatellard
Renata Pankiewicz
Vincent Dechavanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa, Peter Hjelmstrom, Markus Imhof, George Feger, Nigel Jenkins, Phillippe Dupraz, Christine Power, Laurent Magenant, Phillippe Chatellard, Renata Pankiewicz, Vincent Dechavanne filed Critical Merck Serono Sa
Publication of IL204948A0 publication Critical patent/IL204948A0/en
Publication of IL204948A publication Critical patent/IL204948A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL204948A 2007-10-22 2010-04-08 Β - single ifn from one to a mutated fc lgg segment IL204948A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07118980 2007-10-22
US714207P 2007-12-11 2007-12-11
PCT/EP2008/064224 WO2009053368A1 (en) 2007-10-22 2008-10-21 Single ifn-beta fused to a mutated igg fc fragment

Publications (2)

Publication Number Publication Date
IL204948A0 IL204948A0 (en) 2010-11-30
IL204948A true IL204948A (en) 2015-11-30

Family

ID=39048918

Family Applications (1)

Application Number Title Priority Date Filing Date
IL204948A IL204948A (en) 2007-10-22 2010-04-08 Β - single ifn from one to a mutated fc lgg segment

Country Status (6)

Country Link
EP (1) EP2203180B1 (enExample)
JP (1) JP5314033B2 (enExample)
AU (1) AU2008314697B2 (enExample)
ES (1) ES2400107T3 (enExample)
IL (1) IL204948A (enExample)
WO (1) WO2009053368A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4559081B2 (ja) 2002-01-25 2010-10-06 ジーツー セラピーズ リミテッド 抗Ｃ５ａＲ抗体及びその使用
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP4218801A3 (en) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
EP2254911B1 (en) 2008-02-20 2015-11-25 Novo Nordisk A/S Humanized anti-c5ar antibodies
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
JP2013519699A (ja) * 2010-02-16 2013-05-30 ノヴォ ノルディスク アー／エス 因子ｖｉｉｉ融合タンパク質
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
EA201291482A1 (ru) 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
TR201815863T4 (tr) * 2010-11-30 2018-11-21 Chugai Pharmaceutical Co Ltd Sitotoksisiteyi indükleyen terapötik madde.
CN102585013B (zh) * 2011-01-07 2014-04-23 中国人民解放军军事医学科学院生物工程研究所 一种含有ω干扰素的融合蛋白及制备方法
EP3798230B1 (en) 2011-06-06 2022-08-03 Novo Nordisk A/S Therapeutic antibodies
WO2013011062A2 (en) * 2011-07-18 2013-01-24 Novo Nordisk A/S Oscar antagonists
CN109111524B (zh) 2011-10-31 2022-10-28 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
KR102568808B1 (ko) 2014-04-07 2023-08-18 추가이 세이야쿠 가부시키가이샤 면역활성화 항원 결합 분자
AU2015260230A1 (en) 2014-05-13 2016-11-17 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016061562A2 (en) * 2014-10-17 2016-04-21 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
ES2807182T3 (es) * 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
WO2016081746A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
WO2017091683A1 (en) 2015-11-25 2017-06-01 Visterra, Inc. Antibody molecules to april and uses thereof
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
ES2823173T3 (es) 2016-01-27 2021-05-06 Just Biotherapeutics Inc Promotor híbrido y usos del mismo
MX2018010988A (es) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
WO2018185131A2 (en) * 2017-04-05 2018-10-11 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
CA3121699A1 (en) * 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2023330110A1 (en) 2022-08-22 2025-03-06 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ300762B6 (cs) * 1998-10-16 2009-08-05 Biogen Idec Ma Inc. Fúzní proteiny interferonu-beta-1a a jejich použití
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
WO2004004798A2 (en) * 2002-07-03 2004-01-15 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
JP2008527986A (ja) * 2005-01-24 2008-07-31 ラボラトワール セローノ ソシエテ アノニム 炎症及び／又は自己免疫疾患における可溶性ｃｄ１６４の使用
EP1899368A2 (en) * 2005-05-26 2008-03-19 Schering Corporation Interferon-igg fusion

Also Published As

Publication number Publication date
JP5314033B2 (ja) 2013-10-16
ES2400107T3 (es) 2013-04-05
EP2203180B1 (en) 2012-11-21
WO2009053368A1 (en) 2009-04-30
AU2008314697A1 (en) 2009-04-30
EP2203180A1 (en) 2010-07-07
AU2008314697B2 (en) 2013-08-29
IL204948A0 (en) 2010-11-30
JP2011500073A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
IL204948A (en) Β - single ifn from one to a mutated fc lgg segment
EP2118129A4 (en) ISOLATED PHOSPHOLIPID PROTEIN PARTICLES
EP2448972A4 (en) IMMUNOGLOBULIN FC POLYPEPTIDES
IL202128A0 (en) Immunoglobulin fusion proteins
IL202443A0 (en) Rage fusion proteins
IL201791A (en) Interferon-adapted polypeptides in the cell
SI3118220T1 (sl) Protein
GB0721686D0 (en) Polypeptides
SI2173381T1 (sl) Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
IL202441A0 (en) Glass ceramic armor material
ZA201000283B (en) Reinigung pegylierter polypeptide
LT2144924T (lt) Sulieto baltymo vakcina
GB2445928B (en) Retractable handle assembly
GB0725153D0 (en) Protein analysis
GB0725201D0 (en) Peptide fusion proteins
GB0712302D0 (en) Chrondroitinase polypeptides
GB0719492D0 (en) Grinder for electrodes
GB0700759D0 (en) Novel fusion protein
TWI320491B (en) Multifunctional glasses
GB0720563D0 (en) Protein
GB0709707D0 (en) Novel fusion protein
GB0713169D0 (en) Fusion proteins
GB0708151D0 (en) Fused deposition modelling
IL206541A0 (en) Novel protein
EP2178551A4 (en) NEW PEPTIDES

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)